ECSP21067052A - SOLID FORMULATION OF THE CAPSID ASSEMBLY MODULATOR - Google Patents

SOLID FORMULATION OF THE CAPSID ASSEMBLY MODULATOR

Info

Publication number
ECSP21067052A
ECSP21067052A ECSENADI202167052A ECDI202167052A ECSP21067052A EC SP21067052 A ECSP21067052 A EC SP21067052A EC SENADI202167052 A ECSENADI202167052 A EC SENADI202167052A EC DI202167052 A ECDI202167052 A EC DI202167052A EC SP21067052 A ECSP21067052 A EC SP21067052A
Authority
EC
Ecuador
Prior art keywords
capsid assembly
solid formulation
assembly modulator
modulator
capsid
Prior art date
Application number
ECSENADI202167052A
Other languages
Spanish (es)
Inventor
Dominique Verstraete
michael Anne
Abhishek Singh
DYCKE Frederic VAN
Oliver Lenz
Jan Snoeys
Maria Jansens
Claire Balmain
Joris Vandenbossche
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2019/000231 external-priority patent/WO2019175657A1/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of ECSP21067052A publication Critical patent/ECSP21067052A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación se refiere a formas farmacéuticas orales sólidas un inhibidor de ensamblaje de la cápside para el tratamiento de la infección por el virus de la hepatitis B.The present disclosure relates to solid oral dosage forms of a capsid assembly inhibitor for the treatment of hepatitis B virus infection.

ECSENADI202167052A 2019-03-13 2021-09-10 SOLID FORMULATION OF THE CAPSID ASSEMBLY MODULATOR ECSP21067052A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IB2019/000231 WO2019175657A1 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP2019056348 2019-03-13
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP19197566 2019-09-16

Publications (1)

Publication Number Publication Date
ECSP21067052A true ECSP21067052A (en) 2021-11-18

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202167052A ECSP21067052A (en) 2019-03-13 2021-09-10 SOLID FORMULATION OF THE CAPSID ASSEMBLY MODULATOR

Country Status (16)

Country Link
EP (1) EP3937928A1 (en)
JP (1) JP2022524819A (en)
KR (1) KR20210137484A (en)
CN (1) CN113557016A (en)
AU (1) AU2020235442A1 (en)
BR (1) BR112021017525A2 (en)
CA (1) CA3132095A1 (en)
CR (1) CR20210481A (en)
EC (1) ECSP21067052A (en)
IL (1) IL286209A (en)
JO (1) JOP20210250A1 (en)
MA (1) MA55280A (en)
MX (1) MX2021011030A (en)
PE (1) PE20212107A1 (en)
SG (1) SG11202109710QA (en)
WO (1) WO2020183020A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
JP2021515769A (en) * 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Capsid aggregation regulator dosing regimen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP2021515769A (en) * 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Capsid aggregation regulator dosing regimen

Also Published As

Publication number Publication date
KR20210137484A (en) 2021-11-17
CN113557016A (en) 2021-10-26
SG11202109710QA (en) 2021-10-28
WO2020183020A1 (en) 2020-09-17
AU2020235442A1 (en) 2021-08-12
MX2021011030A (en) 2021-10-13
IL286209A (en) 2021-10-31
JP2022524819A (en) 2022-05-10
EP3937928A1 (en) 2022-01-19
JOP20210250A1 (en) 2023-01-30
CR20210481A (en) 2021-10-25
PE20212107A1 (en) 2021-11-04
CA3132095A1 (en) 2020-09-17
MA55280A (en) 2022-01-19
BR112021017525A2 (en) 2021-11-23

Similar Documents

Publication Publication Date Title
CL2021000227A1 (en) Dosage regimen of the capsid assembly modulator. (application divisional 2254-2020)
CO2019001379A2 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of a hiv virus infection.
CR20150454A (en) AMIDA COMPOUNDS FOR HIV TREATMENT
CL2020000501A1 (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and their uses.
UY37252A (en) COMPOUNDS FOR HEPATITIS B VIRUS INFECTION TREATMENT
UY37581A (en) COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
CL2019002204A1 (en) HIV inhibitor compounds.
CL2017001798A1 (en) Pyrazine compounds for the treatment of infectious diseases.
CL2018001996A1 (en) Compositions and methods to modulate the expression of complement factor b (divisional application 2764-16)
CO2018000660A2 (en) Compounds derived from (3β) -cholest-5-en-3-alkyl-3-ol and (3β) -cholest-3-alkyl-3-ol
CO2018000589A2 (en) Oxiesterols and pharmaceutical compositions containing them
ECSP21067052A (en) SOLID FORMULATION OF THE CAPSID ASSEMBLY MODULATOR
CL2012001959A1 (en) Compounds derived from thiophene-2-carboxylic acid, flaviviridae virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment of a viral infection by flaviviridae.
CL2018001199A1 (en) Comprimido de tres capas que comprende un compuesto de formula i, tenofovir alafenamida y emtricitabina; su uso en el tratamiento de una infeccion por vih.
CL2020000487A1 (en) Antiviral agents against hepatitis b.
CO2019009215A2 (en) Hemi-sulfate nucleotide salt for the treatment of hepatitis C virus
CL2014003634A1 (en) Hepatitis C virus inhibitors
UY33897A (en) HEPATITIS C VIRUS INHIBITORS
CL2014000393A1 (en) Compounds derived from benzofuran and its salts, as hepatitis c virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment or prevention of an infection with the hepatitis c virus or a disease associated with said infection.
CL2020001358A1 (en) Modified brucella vaccine strain for the treatment of brucellosis
UY37166A (en) NUCLEOSID ALKYLIN ANALOGS AS INHIBITORS OF HUMAN RINOVIRUS
EA201890818A1 (en) COMBINED TREATMENT FOR HCV TREATMENT
AR111017A1 (en) HEMISULFATE SALT OF A NUCLEOTID COMPOUND FOR THE TREATMENT OF HEPATITIS C VIRUS
AR109364A1 (en) ANTIVIRAL COMPOUNDS
PL409016A1 (en) N-sulfonic derivative of polyallylamine, application of N-sulfonic derivative of polyallylamine as a medicine, preferably for the prevention and treatment of infection by influenza type A (IAV) virus and the pharmaceutical composition containing the N-sulfonic derivate of polyallylamine